ClinicalTrials.gg
Enrolling by invitationNCT07346703DHAMEUpdated Jan 16, 2026

Effects of DHA in Patients With Multiple Sclerosis

An interventional study of Docosahexaenoic Acid (DHA) Dietary Supplement and Docosahexaenoic Acid (DHA) Dietary Supplement in Multiple Sclerosis, Performance Enhancement and Supplemental Nutrition Assistance Program Education, sponsored by Francisco Javier Martínez Noguera. Enrolling by invitation at 1 site in Spain. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Francisco Javier Martínez Noguera · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 230 studies in Multiple Sclerosis with a site in Spain — 35 open to participants now, 56 under way, 14 of them phase 3. Multiple Sclerosis · Spain.

Planned enrollment
112th of 202
100 · median 137
Started
2026
with 11 others
No phase
68 of 230
22 open now
Primary completion
2026-06
later than 21 of 55 live
Registered
215th of 230
by date

Among the 230 studies in Multiple Sclerosis with a site in Spain, this one is the 112th largest by planned enrollment of the 202 interventional ones that give a count, is one of 12 that started in 2026, is one of 68 with no phase, reaches primary completion later than 21 of the 55 other live ones, and was the 215th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

35 of the 230 studies in Multiple Sclerosis with a site in Spain are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Multiple Sclerosis with a site in Spain, or all of them as a file.
02

Study summary

This clinical trial will investigate the effects of combining therapeutic exercise with DHA supplementation in 100 patients with multiple sclerosis using a randomized controlled design. Participants, diagnosed according to the McDonald criteria, will undergo functional, cognitive, fatigue, and quality-of-life assessments through tools such as the EDSS, BRB-N, MFIS, EVA-f, and MSQoL-54. Physiological evaluations will include infrared thermography, isokinetic strength testing, perceived exertion (Modified Borg Scale), balance (Timed Up and Go), lower-limb power (Sit-to-Stand app), and handgrip strength. The study hypothesizes that this combined intervention will improve motor function, cognition, fatigue management, and overall quality of life by enhancing neuromuscular activation and metabolic efficiency.

Read the detailed description

Design

Randomized clinical trial.

Study Period

Two years: from January 2024 to January 2026.

Population Selection Reference Population

The study sample will be recruited from the Multiple Sclerosis Association (AMDEM) in the Region of Murcia and the Neurology Department of Hospital Ribera Salud in Molina de Segura.

Eligible participants will be patients diagnosed with multiple sclerosis (MS) according to the McDonald criteria, aged approximately 18 to 65 years, who have not experienced relapse episodes in the month prior to inclusion, and have an Expanded Disability Status Scale (EDSS) score between 0.0 and 6.0, as well as the ability to voluntarily activate the tibialis anterior muscle.

Sample Size

Given the characteristics of the study, the target sample size is at least 100 participants, divided into four groups (n ≈ 25 per group) according to treatment.

Participants will be randomly assigned to one of four groups, each following a different therapeutic protocol:

Group 1: therapeutic exercise protocol three times per week throughout the study + daily DHA supplementation (4 capsule/day).

Group 2: same exercise protocol + placebo capsule (sunflower oil) identical in appearance, color, and dosage.

Group 3: DHA supplementation only (4 capsule/day).

Group 4: placebo capsule only (sunflower oil), identical to intervention groups.

Statistical Design

A one-way or repeated-measures ANOVA will be used to test for statistically significant differences among three or more dependent samples.

Measurement time points will be defined as follows:

T0: baseline (pre-intervention).

T1: midpoint of the intervention (approximately 1.5 months after initiation).

T2: immediately after completing the 3-month intervention protocol.

T3: 3 months after the end of the intervention.

Data Collection Participant Characteristics

Sensitive data will be collected regarding:

Age, sex, height, weight, medication use, relapse episodes in the months prior to the study, disability status, disease condition, and cognitive function.

Additional psychophysical information will be gathered using validated questionnaires administered before and after the intervention:

Disability will be assessed using the Expanded Disability Status Scale (EDSS).

A score of 0.0 represents normal physical function without disability.

3-4 indicates mild impairment not limiting daily or work activities.

5-6 indicates moderate disability, typically able to walk but requiring assistance for about 100 meters at level 6.

7-9 represents severe impairment, often confined to a wheelchair or bed.

Cognitive function will be assessed using the Brief Repeatable Battery of Neuropsychological Tests (BRB-N), a validated tool for MS. It includes tests of selective recall, the 7/24 spatial recall test, the controlled oral word association test, and the paced auditory serial addition test (PASAT).

Fatigue will be measured using the Modified Fatigue Impact Scale (MFIS), assessing the perceived impact of fatigue on cognitive (10 items), physical (10 items), and psychosocial (20 items) functioning. Responses range from 0 (no problem) to 4 (extreme problem), with a maximum score of 160.

Quality of life will be measured with the Multiple Sclerosis Quality of Life-54 (MSQoL-54), a validated MS-specific scale that evaluates symptom severity, walking ability, absenteeism due to health, hospitalization history, depressive symptoms, and disease duration.

Functional Assessments

Pre, during and post--intervention.

Infrared thermography will capture whole-body thermal images before, during, and after the intervention as a non-invasive, reliable, and cost-effective diagnostic tool. Measurements will be taken:

Pre and post--intervention.

The Modified Borg Scale will be used to adjust exercise load intensity, maintaining perceived exertion between 5-7. If the score falls below 5, resistance will be increased by adding up to 5 kg. This will be recorded in the final session of each week.

The EVA-f scale (adapted fatigue visual analogue scale) will be used to measure subjective fatigue perception (0 = no fatigue; 10 = extreme fatigue) at the end of each training session.

The Sit-to-Stand App Test will be used to assess lower-limb power through video-based analysis of standing-up movements, providing values for time, power, and velocity (pre- and post-protocol).

The Timed Up and Go (TUG) Test will assess balance and fall risk. Participants will stand up from a chair, walk 3 meters, turn around, return, and sit down again. Two repetitions per session will be performed with one-minute rest intervals.

Handgrip strength will be measured (pre- and post-intervention) to assess upper-limb muscle strength.

Isokinetic strength tests will evaluate lower-limb strength (pre- and post-intervention).

Laboratory Tests

Serum analyses will include measurement of interleukin-6,

Blood samples will be collected at four time points:

Pre, during and immediately post-intervention.

03

Conditions studied

  • Multiple Sclerosis
  • Performance Enhancement
  • Supplemental Nutrition Assistance Program Education
  • Strength Outcomes
  • Function Improvement
  • Intervention Study

Browse trials for

Keywords

  • Multiple sclerosis
  • Omega-3
  • nutritional supplements
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The patient sample comes from the Multiple Sclerosis Association (AMDEM) of the Murcia region and the neurology department of the Ribera Salud Hospital in Molina de Segura. Patients diagnosed with multiple sclerosis according to the McDonald criteria, aged between 18 and 65 (approximately), who have not suffered any flare-ups in the previous month and who have a score of 0.00 to 6 on the Expanded Disability Status Scale (EDSS) and are able to activate the tibialis anterior muscle will be eligible for the study.

Exclusion criteria

Exclusion Criteria:

  • Not fulfilling the inclusion criteria.
  • Having any problems performing the tests.
  • Having any problems taking the supplement or placebo.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    DHA

    This group will take 2 g of DHA (4 capsules per day) for 3 months

    Dietary Supplement: Docosahexaenoic Acid (DHA) Dietary Supplement

  • Experimental
    DHA + therapeutic exercise

    This group will take 2 g of DHA (4 capsules per day) + therapeutic exercise for 3 months

    Dietary Supplement: Docosahexaenoic Acid (DHA) Dietary Supplement

  • Placebo comparator
    Sunflower oil

    This group will take a placebo (4 capsules per day) for 3 months.

    Dietary Supplement: Sunflower Oil

  • Placebo comparator
    Sunflower oil + therapeutic exercise

    This group will take a placebo (4 capsules per day) + therapeutic exercise for 3 months.

    Dietary Supplement: Sunflower Oil

Interventions

  • Dietary supplementDocosahexaenoic AcidsStudies of Docosahexaenoic AcidsDocosahexaenoic Acids pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will take 2 g of DHA per day for 3 months.

    Also known as: Omega-3

  • Dietary supplementDocosahexaenoic AcidsStudies of Docosahexaenoic AcidsDocosahexaenoic Acids pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will take 2 g of DHA per day + therapeutic exercise (3 times a week) for 3 months.

  • Dietary supplementSunflower Oil

    Subjects will take 2 g of placebo (sunflower oil) per day for 3 months.

    Also known as: Placebo

  • Dietary supplementSunflower Oil

    Subjects will take 2 g of placebo per day + therapeutic exercise (3 times a week) for 3 months.

06

What researchers measure

Primary outcomes

  1. ISOKINETIC

    Measurement of isokinetic strength in the right leg N/m

    Time frame: Throughout study completion, an average of 12 weeks

Secondary outcomes

  1. Modified Fatigue Impact Scale

    Fatigue is assessed using the Modified Fatigue Impact Scale, which considers the perceived impact of fatigue on cognitive functioning (10 items), physical functioning (10 items) and psychosocial functioning (20 items). It is a self-administered instrument in which subjects are asked to rate the extent to which fatigue has caused them problems (0 = no problem to 4 = extreme problem, maximum score = 160).

    Time frame: Throughout study completion, an average of 12 weeks

  2. MSQoL-54 - Walking Status

    Description: Functional walking status assessed using the walking-related item of the MSQoL-54. Unit of Measure: Categorical (able to walk without assistance / needs assistance / wheelchair dependent).

    Time frame: Throughout study completion, an average of 12 weeks

  3. MSQoL-54 - Days Unable to Work or Attend School Due to Health

    Description: Number of days participants were unable to work or attend school due to health problems during the previous month, assessed via MSQoL-54. Unit of Measure: Days (0, 1-15, 16-30).

    Time frame: Throughout study completion, an average of 12 weeks

  4. MSQoL-54 - Hospital Admission in the Previous Year

    Description: Self-reported hospital admission related to health status in the previous year, assessed via MSQoL-54. Unit of Measure: Binary (yes/no).

    Time frame: Throughout study completion, an average of 12 weeks

  5. MSQoL-54 - Depressive Symptoms

    Description: Presence of self-reported depressive symptoms assessed using the corresponding MSQoL-54 item. Unit of Measure: Binary (yes/no).

    Time frame: Throughout study completion, an average of 12 weeks

  6. THERMOGRAPHY

    Thermography study to capture full-body thermal images will be performed using a Flir E75 camera. The temperature (°C) of the lower limbs will be evaluated by analyzing the images.

    Time frame: Pre, six weeks after the start and after the intervention (12 weeks)

  7. SIT TO STAND TEST

    The Sit to Stand app test will be performed and muscle power will be assessed using the application. This tool is based on video recording of the movement of getting up from a chair. The unit of measurement is meters/seconds.

    Time frame: Throughout study completion, an average of 12 weeks

  8. TIME UP AND GO test

    The Time Up and Go test will be implemented, which is a method of assessing balance ability consisting of several parts, where the patient starts sitting in a chair, then stands up and walks 3 metres, turns around to return to the chair and then sits down, measuring the time it takes to complete the task. Each measurement will be repeated twice with a one-minute rest in between. To perform this test, the patient needs good posture control, coordination and strength in the lower limbs, and balance, movement control and risk of falls are assessed. The unit of measurement is in seconds.

    Time frame: Throughout study completion, an average of 12 weeks

  9. HAND GRIP

    Hand grip to assess upper limb strength through pre- and post-treatment grip strength. The unit of measurement is the kilogram.

    Time frame: Throughout study completion, an average of 12 weeks

  10. IL-6

    Serum interleukin 6 levels will be determined by blood sampling performed by an experienced nurse and analyzed in our reference laboratory.

    Time frame: Pre, six weeks after the start and after the intervention (12 weeks)

  11. MSQoL-54 - Multiple Sclerosis Disease Duration

    Description: Duration of multiple sclerosis since diagnosis. Unit of Measure: Years.

    Time frame: Baseline

07

Study locations

1 site
  • Research Center for High Performance Sport. Universidad Católica de Murcia
    La Ñora, Murcia 30830, Spain
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Jun 2026, 5 months later.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 5 months is below that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2025
First posted
Jan 16, 2026
StartEst.
Jan 2026
Primary completionEst.
Jun 2026
CompletionEst.
Jul 2026
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07346703
Lead sponsor
Francisco Javier Martínez Noguera
Responsible party
Francisco Javier Martínez Noguera (Associate Researcher (Doctor of Sports Nutrition), Universidad Católica San Antonio de Murcia) — Sponsor-investigator
First posted
Jan 16, 2026
Start date
Jan 2026 (estimated)
Primary completion
Jun 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Jan 16, 2026

Study contacts

Francisco Javier Martínez Noguera, Researcher-PhD
study chair · Universidad Católica San Antonio de Murcia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docosahexaenoic Acids

Start the discussion